SAN FRANCISCO, Oct. 05, 2022 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. NRIXa clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced six poster presentations at the upcoming 37th Annual Society for Immunotherapy of Cancer (SITC) meeting, being held November 8-12th In Boston.
“Our presentations at SITC underscore the versatility of our targeted protein modulation platform and applications of our best-in-class CBL-B inhibitors, which include both an orally administered drug, NX-1607, and our DeTIL-0255 infused cell therapy,” said Arthur T. Sands , MD, Ph.D., President and Chief Executive Officer of Nurix. “Regarding NX-1607, we are pleased to present the first biomarker data from our Phase 1 study in patients with advanced malignancies.”
Poster presentation details:
NX-1607 program
- Title: First clinical characterization of novel proximal biomarkers for NX-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced malignancies
Poster #: 777
Authors: Whelan S, Karim C, Ye J, Ingallinera T, Cherala G, Jameson K, Williams A, Sharp A, Krebs MG, Pacey S, Blagden S, Plummer R, Hochhauser D , Evans J, de Bono J, Powers J
Session date and time: Thursday, November 10, 2022, 9:00 a.m. – 9:00 p.m. ET
- Title: A novel small molecule inhibitor of CBL-B shows potent antitumor activity in combination with adoptive cell transfer of Pmel-1 in an aggressive mouse melanoma model
Poster #: 331
Authors: Gallotta M, Gomez Romo J, Ranucci S, Tenn-McClellan A, Cohen F, Hansen GM, Sands AT, Rountree R, Guiducci C.
Session date and time: Thursday, November 10, 2022, 9:00 a.m. – 9:00 p.m. ET
- Title: NX-1607, a small molecule inhibitor of CBL-B E3 ubiquitin ligase, promotes T and NK cell activation and enhances NK-mediated ADCC in a mouse lymphoma tumor model
Poster #: 824
Authors: Gallotta M, Gosling J, Tenn-McClellan A, Ranucci S, Gomez Romo J,…
